** Shares of U.S. drugmaker Eli Lilly LLY.N rise 2.11% to $900.01 premarket
** The company says it has begun selling vials of higher dosages of its popular weight-loss drug Zepbound, which is typically sold in auto-injector pens, in the U.S.
** The vials are priced at a $150 discount to the cost of the injector pen version
** Says patients can purchase 7.5 mg and 10mg vials of Zepbound for $499 a month on from its B2C LillyDirect website
** Last August, co launched two lower dose vials of Zepbound to help increase availability
** Says it had reduced prices for a month's supply of lower dosage vials by around $50
** LLY rose 14.5% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.